Buy Or Sell Opportunity • Jun 23
Now 22% overvalued after recent price rise Over the last 90 days, the stock has risen 61% to ₹266. The fair value is estimated to be ₹218, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 10%. For the next 3 years, revenue is forecast to grow by 14% per annum. Earnings are also forecast to grow by 18% per annum over the same time period. Board Change • Jun 01
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 3 highly experienced directors. Independent Director Srinivas Mishra was the last director to join the board, commencing their role in 2025. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Price Target Changed • May 28
Price target increased by 18% to ₹266 Up from ₹225, the current price target is an average from 3 analysts. New target price is 6.9% above last closing price of ₹249. Stock is down 4.4% over the past year. The company is forecast to post earnings per share of ₹11.85 for next year compared to ₹9.22 last year. Reported Earnings • May 27
Full year 2026 earnings: EPS and revenues exceed analyst expectations Full year 2026 results: EPS: ₹9.22 (up from ₹8.40 in FY 2025). Revenue: ₹30.3b (up 16% from FY 2025). Net income: ₹4.18b (up 9.8% from FY 2025). Profit margin: 14% (in line with FY 2025). Revenue exceeded analyst estimates by 1.8%. Earnings per share (EPS) also surpassed analyst estimates by 7.6%. Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has increased by 43% per year, which means it is tracking significantly ahead of earnings growth. Annuncio • May 26
Marksans Pharma Limited Recommends Final Dividend for the Financial Year 2025-26 Marksans Pharma Limited at its board of directors meeting held on May 26, 2026, recommended a final dividend of INR 0.90 per Equity Share of face value of INR 1.00 per share (90%) for the financial year 2025-26. The dividend, if approved by the Members at the forthcoming Annual General Meeting (‘AGM’) will be credited /dispatched within 30 days from the date of AGM. Valuation Update With 7 Day Price Move • May 26
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹254, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 218% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₹163 per share. Annuncio • May 12
Marksans Pharma Limited to Report Q4, 2026 Results on May 26, 2026 Marksans Pharma Limited announced that they will report Q4, 2026 results on May 26, 2026 Buy Or Sell Opportunity • May 06
Now 20% overvalued after recent price rise Over the last 90 days, the stock has risen 9.4% to ₹196. The fair value is estimated to be ₹163, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 11%. Revenue is forecast to grow by 33% in 2 years. Earnings are forecast to grow by 57% in the next 2 years. Reported Earnings • Feb 06
Third quarter 2026 earnings: EPS exceeds analyst expectations Third quarter 2026 results: EPS: ₹2.50 (up from ₹2.31 in 3Q 2025). Revenue: ₹7.75b (up 14% from 3Q 2025). Net income: ₹1.13b (up 8.3% from 3Q 2025). Profit margin: 15% (in line with 3Q 2025). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 6.4%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has increased by 40% per year, which means it is tracking significantly ahead of earnings growth. Annuncio • Jan 09
Marksans Pharma Limited to Report Q3, 2026 Results on Feb 05, 2026 Marksans Pharma Limited announced that they will report Q3, 2026 results on Feb 05, 2026 Reported Earnings • Nov 15
Second quarter 2026 earnings released: EPS: ₹2.17 (vs ₹2.13 in 2Q 2025) Second quarter 2026 results: EPS: ₹2.17 (up from ₹2.13 in 2Q 2025). Revenue: ₹7.42b (up 16% from 2Q 2025). Net income: ₹982.5m (up 1.6% from 2Q 2025). Profit margin: 13% (down from 15% in 2Q 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 53% per year, which means it is tracking significantly ahead of earnings growth. Buy Or Sell Opportunity • Nov 04
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 13% to ₹187. The fair value is estimated to be ₹237, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 18%. Revenue is forecast to grow by 26% in 2 years. Earnings are forecast to grow by 45% in the next 2 years. Annuncio • Oct 23
Marksans Pharma Limited to Report Q2, 2026 Results on Nov 13, 2025 Marksans Pharma Limited announced that they will report Q2, 2026 results on Nov 13, 2025 Valuation Update With 7 Day Price Move • Aug 12
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₹187, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 31x in the Pharmaceuticals industry in India. Total returns to shareholders of 258% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₹259 per share. Upcoming Dividend • Jul 25
Upcoming dividend of ₹0.80 per share Eligible shareholders must have bought the stock before 01 August 2025. Payment date: 07 September 2025. Payout ratio is a comfortable 9.5% but the company is paying out more than the cash it is generating. Trailing yield: 0.4%. Lower than top quartile of Indian dividend payers (1.2%). Lower than average of industry peers (0.8%). Annuncio • Jul 24
Marksans Pharma Limited to Report Q1, 2026 Results on Aug 12, 2025 Marksans Pharma Limited announced that they will report Q1, 2026 results on Aug 12, 2025 Reported Earnings • Jul 18
Full year 2025 earnings: Revenues and EPS in line with analyst expectations Full year 2025 results: EPS: ₹8.40 (up from ₹6.92 in FY 2024). Revenue: ₹26.2b (up 21% from FY 2024). Net income: ₹3.81b (up 21% from FY 2024). Profit margin: 14% (in line with FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst expectations. Revenue is forecast to grow 17% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 73% per year, which means it is tracking significantly ahead of earnings growth. Annuncio • Jul 13
Marksans Pharma Limited announces Annual dividend, payable on September 07, 2025 Marksans Pharma Limited announced Annual dividend of INR 0.8000 per share payable on September 07, 2025, ex-date on August 01, 2025 and record date on August 01, 2025. Annuncio • Jul 11
Marksans Pharma Limited, Annual General Meeting, Aug 08, 2025 Marksans Pharma Limited, Annual General Meeting, Aug 08, 2025, at 09:00 Indian Standard Time. Reported Earnings • May 21
Full year 2025 earnings: Revenues and EPS in line with analyst expectations Full year 2025 results: EPS: ₹8.40 (up from ₹6.92 in FY 2024). Revenue: ₹26.9b (up 24% from FY 2024). Net income: ₹3.81b (up 21% from FY 2024). Profit margin: 14% (in line with FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst expectations. Revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 75% per year, which means it is tracking significantly ahead of earnings growth. Annuncio • May 10
Marksans Pharma Limited to Report Q4, 2025 Results on May 19, 2025 Marksans Pharma Limited announced that they will report Q4, 2025 results on May 19, 2025 Buy Or Sell Opportunity • Apr 24
Now 25% overvalued Over the last 90 days, the stock has fallen 9.7% to ₹228. The fair value is estimated to be ₹183, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years. Earnings per share has grown by 18%. Revenue is forecast to grow by 39% in 2 years. Earnings are forecast to grow by 57% in the next 2 years. Valuation Update With 7 Day Price Move • Apr 10
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₹195, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 28x in the Pharmaceuticals industry in India. Total returns to shareholders of 243% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₹184 per share. New Risk • Apr 09
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (8.6% average weekly change). Buy Or Sell Opportunity • Mar 24
Now 24% overvalued Over the last 90 days, the stock has fallen 22% to ₹228. The fair value is estimated to be ₹184, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years. Earnings per share has grown by 18%. Revenue is forecast to grow by 38% in 2 years. Earnings are forecast to grow by 56% in the next 2 years. New Risk • Mar 10
New minor risk - Dividend sustainability The company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 0.3% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company. Reported Earnings • Feb 12
Third quarter 2025 earnings released: EPS: ₹2.31 (vs ₹1.84 in 3Q 2024) Third quarter 2025 results: EPS: ₹2.31 (up from ₹1.84 in 3Q 2024). Revenue: ₹7.10b (up 21% from 3Q 2024). Net income: ₹1.05b (up 26% from 3Q 2024). Profit margin: 15% (in line with 3Q 2024). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 69% per year, which means it is tracking significantly ahead of earnings growth. Buy Or Sell Opportunity • Jan 29
Now 25% overvalued Over the last 90 days, the stock has fallen 18% to ₹236. The fair value is estimated to be ₹190, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years. Earnings per share has grown by 14%. Revenue is forecast to grow by 40% in 2 years. Earnings are forecast to grow by 58% in the next 2 years. Annuncio • Jan 22
Marksans Pharma Limited to Report Nine Months, 2025 Results on Feb 11, 2025 Marksans Pharma Limited announced that they will report nine months, 2025 results on Feb 11, 2025 Annuncio • Nov 25
Marksans Pharma Limited Receives USFDA Approval for Loratadine Tablets USP 10 mg Marksans Pharma Limited announced the final approval of the Company's Abbreviated New Drug Application for Loratadine Tablets USP 10 mg from USFDA. They are indicated for the treatment of allergic rhinitis caused by pollen and upper respiratory tract allergy for over-the-counter use. This product is generic version of Clartin tablet in the same strength of Bayer Healthcare. Loratadine is an antihistamine that treats symptoms such as itching, runny nose, watery eyes, and sneezing from "hay fever" and other allergies. Price Target Changed • Nov 15
Price target increased by 26% to ₹330 Up from ₹261, the current price target is an average from 3 analysts. New target price is 7.5% above last closing price of ₹307. Stock is up 119% over the past year. The company is forecast to post earnings per share of ₹8.75 for next year compared to ₹6.92 last year. Reported Earnings • Nov 13
Second quarter 2025 earnings released: EPS: ₹2.13 (vs ₹1.84 in 2Q 2024) Second quarter 2025 results: EPS: ₹2.13 (up from ₹1.84 in 2Q 2024). Revenue: ₹6.53b (up 23% from 2Q 2024). Net income: ₹967.2m (up 16% from 2Q 2024). Profit margin: 15% (in line with 2Q 2024). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 73% per year, which means it is tracking significantly ahead of earnings growth. Annuncio • Oct 23
Marksans Pharma Limited to Report Q2, 2025 Results on Nov 12, 2024 Marksans Pharma Limited announced that they will report Q2, 2025 results on Nov 12, 2024 Annuncio • Sep 25
Marksans Pharma Limited Approves Dividend for the Year Ended March 31, 2024 Marksans Pharma Limited at its Annual General Meeting held on September 24, 2024, approved to declare dividend on equity shares recommended by the Board of Directors at its meeting held on May 30, 2024. The Board of Directors recommended equity dividend of INR 0.60 (60%) per equity share of INR 1 each face value for the year ended March 31, 2024. Upcoming Dividend • Sep 10
Upcoming dividend of ₹0.60 per share Eligible shareholders must have bought the stock before 17 September 2024. Payment date: 05 October 2024. Payout ratio is a comfortable 8.7% but the company is paying out more than the cash it is generating. Trailing yield: 0.2%. Lower than top quartile of Indian dividend payers (1.1%). Lower than average of industry peers (0.6%). Board Change • Sep 01
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 3 highly experienced directors. Independent Director Shailaja Vardhan was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Buy Or Sell Opportunity • Aug 28
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 63% to ₹240. The fair value is estimated to be ₹198, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years. Earnings per share has grown by 11%. Revenue is forecast to grow by 41% in 2 years. Earnings are forecast to grow by 54% in the next 2 years. Annuncio • Aug 20
Successful Closure of US FDA Inspection At Marksans Pharma's Manufacturing Facility Located At Verna, Goa Marksans Pharma Limited announced that on the inspection conducted by the USFDA at the manufacturing facility of the Company located at Plot No. L-82 & L-83, Verna Industrial estate, Verna, Goa, India from April 09, 2024 to April 17, 2024, the USFDA has issued an Establishment Inspection Report ("EIR") for the said manufacturing facility and the inspection has now been successfully closed by the USFDA. USFDA has determined that the inspection classification of this facility is "Voluntary Action Indicated" (VAI). Valuation Update With 7 Day Price Move • Aug 20
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₹221, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 34x in the Pharmaceuticals industry in India. Total returns to shareholders of 218% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₹198 per share. New Risk • Aug 14
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (126% cash payout ratio). Share price has been volatile over the past 3 months (8.2% average weekly change). Annuncio • Aug 14
Marksans Pharma Limited, Annual General Meeting, Sep 24, 2024 Marksans Pharma Limited, Annual General Meeting, Sep 24, 2024, at 09:30 Indian Standard Time. Reported Earnings • Aug 14
First quarter 2025 earnings released: EPS: ₹1.96 (vs ₹1.52 in 1Q 2024) First quarter 2025 results: EPS: ₹1.96 (up from ₹1.52 in 1Q 2024). Revenue: ₹6.06b (up 21% from 1Q 2024). Net income: ₹887.5m (up 29% from 1Q 2024). Profit margin: 15% (in line with 1Q 2024). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has increased by 44% per year, which means it is tracking significantly ahead of earnings growth. Annuncio • Jul 31
Marksans Pharma Limited to Report Q1, 2025 Results on Aug 13, 2024 Marksans Pharma Limited announced that they will report Q1, 2025 results on Aug 13, 2024 Buy Or Sell Opportunity • Jul 30
Now 20% overvalued after recent price rise Over the last 90 days, the stock has risen 23% to ₹205. The fair value is estimated to be ₹170, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 7.6%. For the next 3 years, revenue is forecast to grow by 16% per annum. Earnings are also forecast to grow by 21% per annum over the same time period. Valuation Update With 7 Day Price Move • Jul 05
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₹188, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 32x in the Pharmaceuticals industry in India. Total returns to shareholders of 114% over the past three years. Recent Insider Transactions • Jun 08
Whole-time Director recently bought ₹6.9m worth of stock On the 3rd of June, Sandra Saldanha bought around 47k shares on-market at roughly ₹146 per share. This transaction amounted to 21% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. Reported Earnings • Jun 04
Full year 2024 earnings: EPS misses analyst expectations Full year 2024 results: EPS: ₹6.92 (up from ₹6.39 in FY 2023). Revenue: ₹22.3b (up 20% from FY 2023). Net income: ₹3.14b (up 18% from FY 2023). Profit margin: 14% (in line with FY 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 6.0%. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 27% per year, which means it is tracking significantly ahead of earnings growth. Annuncio • May 30
Marksans Pharma Limited Recommends Final Dividend for the Financial Year 2023-24 Marksans Pharma Limited announced that at its Board of Directors meeting held on May 30, 2024, recommended a final dividend of INR 0.60 per Equity Share (face value INR 1 per share) for the financial year 2023-24. The dividend, if approved by the Members at the forthcoming Annual General Meeting ("AGM") will be credited /dispatched within 30 days from the date of AGM. Annuncio • May 15
Marksans Pharma Limited to Report Q4, 2024 Results on May 30, 2024 Marksans Pharma Limited announced that they will report Q4, 2024 results on May 30, 2024 Reported Earnings • Feb 14
Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Third quarter 2024 results: EPS: ₹1.84 (up from ₹1.56 in 3Q 2023). Revenue: ₹5.91b (up 23% from 3Q 2023). Net income: ₹832.4m (up 34% from 3Q 2023). Profit margin: 14% (up from 13% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 6.1%. Earnings per share (EPS) missed analyst estimates by 3.7%. Revenue is forecast to grow 19% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has increased by 42% per year, which means it is tracking significantly ahead of earnings growth. Buy Or Sell Opportunity • Feb 13
Now 23% overvalued after recent price rise Over the last 90 days, the stock has risen 18% to ₹158. The fair value is estimated to be ₹128, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 7.4%. Revenue is forecast to grow by 20% in a year. Earnings are forecast to grow by 25% in the next year. Annuncio • Jan 17
Marksans Pharma Limited to Report Q3, 2024 Results on Feb 13, 2024 Marksans Pharma Limited announced that they will report Q3, 2024 results on Feb 13, 2024 Valuation Update With 7 Day Price Move • Dec 01
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹166, the stock trades at a trailing P/E ratio of 25.3x. Average trailing P/E is 32x in the Pharmaceuticals industry in India. Total returns to shareholders of 163% over the past three years. Reported Earnings • Nov 10
Second quarter 2024 earnings released: EPS: ₹1.84 (vs ₹1.52 in 2Q 2023) Second quarter 2024 results: EPS: ₹1.84 (up from ₹1.52 in 2Q 2023). Revenue: ₹5.50b (up 22% from 2Q 2023). Net income: ₹835.2m (up 36% from 2Q 2023). Profit margin: 15% (up from 14% in 2Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has increased by 38% per year, which means it is tracking significantly ahead of earnings growth. Annuncio • Oct 28
Marksans Pharma Limited to Report Q2, 2024 Results on Nov 09, 2023 Marksans Pharma Limited announced that they will report Q2, 2024 results on Nov 09, 2023 Annuncio • Aug 23
Marksans Pharma Ltd. Receives USFDA Approval for Guaifenesin Extended-Release Tablets Marksans Pharma Ltd. announced that it has received final approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Guaifenesin Extended-Release Tablets, 600 mg and 1200 mg (OTC) The Guaifenesin Extended-Release Tablets, 600 mg and 1200 mg (OTC) are bioequivalent to the reference listed drug (RLD), Mucinex Extended-Release Tablets, 600 mg and 1200 mg, of RB Health (US) LLC. Guaifenesin extended-release tablets help to loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive. The company expects to launch the product immediately. Annuncio • Aug 10
Marksans Pharma Limited Recommends Payment of Dividend for the Financial Year 2022-23 Marksans Pharma Limited recommended to ratify payment of dividend on equity shares for the financial year 2022-23 declared by the Board of Directors at its meeting held on 30th May, 2023. The Board of Directors declared equity dividend of INR 0.50 (50%) per equity share of INR 1/- each face value. Reported Earnings • Aug 09
Full year 2023 earnings released: EPS: ₹6.39 (vs ₹4.56 in FY 2022) Full year 2023 results: EPS: ₹6.39 (up from ₹4.56 in FY 2022). Revenue: ₹18.5b (up 24% from FY 2022). Net income: ₹2.65b (up 42% from FY 2022). Profit margin: 14% (up from 13% in FY 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 34% per year, which means it is tracking significantly ahead of earnings growth. Board Change • Jul 22
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 2 highly experienced directors. Non-Executive Director & Non-Independent Sunny Sharma was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • Jul 17
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹106, the stock trades at a trailing P/E ratio of 18.2x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 179% over the past three years. Annuncio • Jul 12
Marksans Pharma Limited Announces That It Has Received Final Approval from the Us Food and Drug Administration for Its Abbreviated New Drug Application for Acetaminophen and Ibuprofen Tablets, 250 Mg/125 Mg Marksans Pharma Limited announced that it has received final approval from the US Food and Drug Administration for its Abbreviated New Drug Application for Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg, over the counter ("OTC) bioequivalent of Advil Dual Action Tablets 250 mg/125 mg. The Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg (OTC) are bioequivalent to the reference listed drug (RLD), Advil Dual Action of GlaxoSmithKline Consumer Healthcare Holdings (US) LLC.Advil Dual Action was first available as an over-the-counter drug in 2020. The pivotal approval, Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg provides relief for multiple pain-related symptoms by combining two powerful ingredients indicated for OTC pain relief, ibuprofen and acetaminophen. Ibuprofen works through the body targeting pain at the source while Acetaminophen blocks pain signal to the brain. The innovation takes these two powerful pain fighting ingredients and combines them into one tablet to offer fast, strong pain relief. The company plans to launch the product immediately. Annuncio • May 31
Marksans Pharma Limited Approves Declaration of Dividend for the Financial Year 2022-23, Payable on or After 12 June, 2023 Marksans Pharma Limited announced that the Board of Directors of the Company, at meeting held on 30 May 2022 has approved declaration of dividend @ INR 0.50 (Rupee Zero and Paise Fifty) that is 50% per equity share of INR 1 each face value for the financial year 2022-23 have been approved by the Board of Directors. The payment of the dividend shall be made on or after 12 June, 2023 to all the members of the Company whose names has been entered on Record Date that is 7 June, 2023 . Reported Earnings • May 31
Full year 2023 earnings released: EPS: ₹6.41 (vs ₹4.56 in FY 2022) Full year 2023 results: EPS: ₹6.41 (up from ₹4.56 in FY 2022). Revenue: ₹19.1b (up 28% from FY 2022). Net income: ₹2.66b (up 43% from FY 2022). Profit margin: 14% (up from 13% in FY 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 43% per year, which means it is tracking significantly ahead of earnings growth. Annuncio • May 17
Marksans Pharma Limited to Report Q4, 2023 Results on May 30, 2023 Marksans Pharma Limited announced that they will report Q4, 2023 results on May 30, 2023 Reported Earnings • Feb 14
Third quarter 2023 earnings released: EPS: ₹1.56 (vs ₹1.20 in 3Q 2022) Third quarter 2023 results: EPS: ₹1.56 (up from ₹1.20 in 3Q 2022). Revenue: ₹4.97b (up 37% from 3Q 2022). Net income: ₹623.1m (up 29% from 3Q 2022). Profit margin: 13% (in line with 3Q 2022). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 53% per year, which means it is tracking significantly ahead of earnings growth. Annuncio • Feb 03
Marksans Pharma Limited to Report Q3, 2023 Results on Feb 13, 2023 Marksans Pharma Limited announced that they will report Q3, 2023 results on Feb 13, 2023 Annuncio • Jan 20
Marksans Pharma Limited announced that it has received funding from OrbiMed Asia IV Mauritius FVCI Limited Marksans Pharma Limited announced a private placement of 50,324,324 warrants on June 15, 2021. The transaction will include participation from Mark Saldanha for 1,000,000 warrants and OrbiMed Asia IV Mauritius FVCI Limited for 49,324,324 warrants at a price of INR 74 per convertible warrant including premium. The company will issue warrants on preferential allotment basis. Te transaction has been approved by board of directors of the company. Reported Earnings • Nov 18
Second quarter 2023 earnings released: EPS: ₹1.52 (vs ₹1.11 in 2Q 2022) Second quarter 2023 results: EPS: ₹1.52 (up from ₹1.11 in 2Q 2022). Revenue: ₹4.53b (up 25% from 2Q 2022). Net income: ₹612.5m (up 32% from 2Q 2022). Profit margin: 14% (in line with 2Q 2022). Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has increased by 53% per year, which means it is tracking significantly ahead of earnings growth. Annuncio • Nov 03
Marksans Pharma Limited to Report Q2, 2023 Results on Nov 14, 2022 Marksans Pharma Limited announced that they will report Q2, 2023 results on Nov 14, 2022 Annuncio • Oct 12
Marksans Pharma Limited (BSE:524404) entered into a Business Transfer Agreement to acquire Bulk Pharmaceutical Business of Tevapharm India Private Limited. Marksans Pharma Limited (BSE:524404) entered into a Business Transfer Agreement to acquire Bulk Pharmaceutical Business of Tevapharm India Private Limited on Ocotber 11, 2022. The transaction is in cash consideration and Marksans has agreed to retain the site employees with existing terms of employment. The transaction is subject to the usual closing conditions. The transaction is expected to be finalized by April 1, 2023. Torreya acted as the exclusive financial advisor to Marksans Pharma Limited on their acquisition. Annuncio • Aug 30
Marksans Pharma Limited Declares Dividend, Payable on or After 20 September 2022 Marksans Pharma Limited announced that at its AGM held on 29 August 2022, declared dividend of INR 0.25 (that is 25%) on equity shares of INR 1 each face value. The dividend will be paid on or after 20 September 2022. Upcoming Dividend • Aug 12
Upcoming dividend of ₹0.25 per share Eligible shareholders must have bought the stock before 19 August 2022. Payment date: 28 September 2022. Payout ratio is a comfortable 5.5% and this is well supported by cash flows. Trailing yield: 0.5%. Lower than top quartile of Indian dividend payers (1.7%). Lower than average of industry peers (1.0%). Reported Earnings • Aug 08
Full year 2022 earnings released: EPS: ₹4.56 (vs ₹5.83 in FY 2021) Full year 2022 results: EPS: ₹4.56 (down from ₹5.83 in FY 2021). Revenue: ₹14.9b (up 8.3% from FY 2021). Net income: ₹1.87b (down 22% from FY 2021). Profit margin: 13% (down from 17% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 39% per year whereas the company’s share price has increased by 43% per year. Annuncio • Aug 02
Marksans Pharma Limited to Report Q1, 2023 Results on Aug 13, 2022 Marksans Pharma Limited announced that they will report Q1, 2023 results on Aug 13, 2022 Annuncio • Jul 30
Marksans Pharma Limited, Annual General Meeting, Aug 29, 2022 Marksans Pharma Limited, Annual General Meeting, Aug 29, 2022, at 09:00 Indian Standard Time. Annuncio • Jul 21
Marksans Pharma Limited Announces US FDA Approval for Pregabalin Capsules Marksans Pharma Limited announced that it has received final approval from US Food & Drugs Administration for its Abbreviated New Drug Application (ANDA) for Pregabalin Capsules, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, and 300 mg. The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Lyrica Capsules, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, and 300 mg, of Upjohn US 2 LLC. Annuncio • Jul 09
Marksans Pharma Limited (BSE:524404) announces an Equity Buyback for INR 600 million worth of its shares. Marksans Pharma Limited (BSE:524404) announces a share repurchase program. Under the program, the company will repurchase up to INR 600 million worth of its shares. The shares will be repurchased at a price of INR 60 per share. As of July 8, 2022, the company had 409,313,698 shares in issue. Valuation Update With 7 Day Price Move • Jul 05
Investor sentiment improved over the past week After last week's 16% share price gain to ₹49.45, the stock trades at a trailing P/E ratio of 10.8x. Average trailing P/E is 21x in the Pharmaceuticals industry in India. Total returns to shareholders of 159% over the past three years. Annuncio • Jun 11
Marksans Pharma Limited (BSE:524404) completed the acquisition of Access Healthcare for Medical Products LLC. Marksans Pharma Limited (BSE:524404) has signed agreement to acquire Access Healthcare for Medical Products LLC for AED 13 million on April 23, 2022. Access Healthcare has net-worth of AED 1.53 million as on June 30, 2021. The transaction will be funded from internal accruals. For year ended December, 2021, Access Healthcare for Medical Products posted revenues of AED 12 Million and a profit after tax of AED 4.5 Million. Access Healthcare for Medical Products has no debt on its books. The transaction is subject to regulatory approval. The transaction has been approved by board of Marksans Pharma. The acquisition is expected to be completed by June 30, 2022.
Marksans Pharma Limited (BSE:524404) completed the acquisition of Access Healthcare for Medical Products LLC on June 10, 2022. Annuncio • Jun 01
Marksans Pharma Recommends Final Dividend for the Financial Year Ended 31st March, 2022 Marksans Pharma Limited's board of directors meeting held on May 30, 2022 recommended final dividend @ Re. 0.25 i.e. 25% per equity share of INR 1 each face value for the financial year ended 31st March, 2022, subject To Approve the shareholders in the upcoming Annual General Meeting. Reported Earnings • May 31
Full year 2022 earnings: EPS and revenues miss analyst expectations Full year 2022 results: EPS: ₹4.51 (down from ₹5.83 in FY 2021). Revenue: ₹15.3b (up 11% from FY 2021). Net income: ₹1.87b (down 22% from FY 2021). Profit margin: 12% (down from 17% in FY 2021). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 8.2%. Earnings per share (EPS) also missed analyst estimates by 25%. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has only increased by 29% per year, which means it is significantly lagging earnings growth. Annuncio • May 17
Marksans Pharma Limited to Report Fiscal Year 2022 Results on May 30, 2022 Marksans Pharma Limited announced that they will report fiscal year 2022 results on May 30, 2022 Annuncio • Apr 26
Marksans Pharma Limited (BSE:524404) has signed agreement to acquire share capital of Access Healthcare for Medical Products LLC for AED 13 million. Marksans Pharma Limited (BSE:524404) has signed agreement to acquire Access Healthcare for Medical Products LLC for AED 13 million on April, 23, 2022. Access Healthcare has net-worth of AED 1.53 million as on June 30, 2021. The transaction will be funded from internal accruals. For year ended December, 2021, Access Healthcare for Medical Products posted revenues of AED 12 Million and a profit after tax of AED 4.5 Million. Access Healthcare for Medical Products has no debt on its books. The transaction is subject to regulatory approval. The transaction has been approved by board of Marksans Pharma. The acquisition is expected to be completed by June 30, 2022. Valuation Update With 7 Day Price Move • Apr 05
Investor sentiment improved over the past week After last week's 19% share price gain to ₹55.55, the stock trades at a trailing P/E ratio of 9.6x. Average trailing P/E is 25x in the Pharmaceuticals industry in India. Total returns to shareholders of 121% over the past three years. Valuation Update With 7 Day Price Move • Feb 24
Investor sentiment deteriorated over the past week After last week's 16% share price decline to ₹43.90, the stock trades at a trailing P/E ratio of 7.6x. Average trailing P/E is 23x in the Pharmaceuticals industry in India. Total returns to shareholders of 92% over the past three years. Reported Earnings • Feb 13
Third quarter 2022 earnings: EPS and revenues miss analyst expectations Third quarter 2022 results: EPS: ₹1.20 (down from ₹1.42 in 3Q 2021). Revenue: ₹3.75b (up 5.5% from 3Q 2021). Net income: ₹482.7m (down 18% from 3Q 2021). Profit margin: 13% (down from 17% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 8.2%. Earnings per share (EPS) also missed analyst estimates by 25%. Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has only increased by 31% per year, which means it is significantly lagging earnings growth. Annuncio • Feb 03
Marksans Pharma Limited to Report Q3, 2022 Results on Feb 11, 2022 Marksans Pharma Limited announced that they will report Q3, 2022 results on Feb 11, 2022 Reported Earnings • Nov 11
Second quarter 2022 earnings released: EPS ₹1.11 (vs ₹1.21 in 2Q 2021) The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2022 results: Revenue: ₹3.70b (up 2.7% from 2Q 2021). Net income: ₹462.9m (down 8.8% from 2Q 2021). Profit margin: 13% (down from 14% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has only increased by 26% per year, which means it is significantly lagging earnings growth. Reported Earnings • Aug 15
First quarter 2022 earnings released: EPS ₹1.51 (vs ₹1.20 in 1Q 2021) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2022 results: Revenue: ₹3.49b (up 5.4% from 1Q 2021). Net income: ₹626.0m (up 27% from 1Q 2021). Profit margin: 18% (up from 15% in 1Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has only increased by 33% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Aug 11
Investor sentiment deteriorated over the past week After last week's 15% share price decline to ₹71.90, the stock trades at a trailing P/E ratio of 12.5x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 137% over the past three years. Annuncio • Jul 25
Marksans Pharma Limited announced that it has received INR 930.999994 million in funding from OrbiMed Asia IV Mauritius FVCI Limited and other investor On July 23, 2021, Marksans Pharma Limited closed the transaction. Annuncio • Jun 16
Marksans Pharma Limited announced that it expects to receive INR 930.999994 million in funding Marksans Pharma Limited (BSE:524404) announced a private placement of 5,03,24,324 warrants at a price of 18.5? per warrant for the gross proceeds of INR 930,999,994 on June 15, 2021. The transaction will include participation from Mark Saldanha for 10,00,000 warrants and OrbiMed Asia IV Mauritius FVCI Limited for 4,93,24,324 warrants. The company will issue warrants on preferential allotment basis. The warrants to be issued will be convertible into shares of the company within eighteen months from the date of issue. The company will receive 25% amount of the warrant as upfront payment as per the Securities Exchange board of India (Disclosure and Investor Protection, Guidelines 2000) and the balance 75% will be received at the time of exercise of warrants. The transaction has been approved by board of directors. Valuation Update With 7 Day Price Move • Jun 11
Investor sentiment improved over the past week After last week's 17% share price gain to ₹83.70, the stock trades at a trailing P/E ratio of 14.5x. Average trailing P/E is 24x in the Pharmaceuticals industry in India. Total returns to shareholders of 172% over the past three years. Reported Earnings • Jun 03
Full year 2021 earnings released: EPS ₹5.76 (vs ₹2.95 in FY 2020) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹13.8b (up 21% from FY 2020). Net income: ₹2.39b (up 98% from FY 2020). Profit margin: 17% (up from 11% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has only increased by 40% per year, which means it is significantly lagging earnings growth.